EMBL Ventures Closes $55M Fund | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – EMBL ventures, the venture capital arm of the European Molecular Biology Laboratory, today announced the €40 million ($55 million) first close of its EMBL Technology Fund II.

The venture arm of Heidelberg, Germany-based EMBL will remain focused on investments in European biotech and medtech companies and said that it intends to commit between €2 million and €5 million per investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.